1.115USD+1.36%Mkt Cap: 328.49M USDP/E: —Last update: 2026-05-26
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. T…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap328.49M USD
Enterprise Value151.49M USD
Revenue (TTM)55.87M USD
Gross Profit49.68M USD
Net Income (TTM)-52.49M USD
Revenue/Share0.2540 USD
Last Price1.115 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees122
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA-1.87
EV/Revenue2.71
P/S5.85
P/B1.30
EPS (TTM)-0.29
EPS (Forward)-0.58
52W Range
0.483024% of range3.070
52W High3.070 USD
52W Low0.4830 USD
Profitability
Gross Margin92.99%
Oper. Margin-313.85%
EBITDA Margin-145.27%
Profit Margin-98.25%
ROE-21.73%
ROA-18.96%
Growth
Revenue Growth21.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-58.13M USD
CapEx (TTM)155.00K USD
FCF Margin-89.68%
FCF Yield-15.25%
Net Debt-175.53M USD
Net Debt/EBITDA2.16
Balance Sheet
Debt/Equity0.01
Current Ratio6.47
Quick Ratio6.20
Book Value/Sh0.8570 USD
Cash/Share0.6250 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)10.00 USD
Target Range10.00 USD – 10.00 USD
# Analysts3
Ownership
Shares Out.294.61M
Float210.95M
Insiders7.09%
Institutions83.80%
Short Interest
Short Ratio8.7d
Short % Float11.48%
Short % Out.10.35%
Shares Short29.26M
Short (prev mo.)26.47M
Technical
SMA 501.460 (-23.6%)
SMA 2001.676 (-33.5%)
Beta0.71
S&P 52W Chg28.31%
Avg Vol (30d)2.43M
Avg Vol (10d)3.98M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—